<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38963942</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0023</ISSN><JournalIssue CitedMedium="Internet"><Volume>181</Volume><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cytokine</Title><ISOAbbreviation>Cytokine</ISOAbbreviation></Journal><ArticleTitle>Circulating calprotectin as a potential biomarker of persistent olfactory dysfunctions in Post-COVID-19 patients.</ArticleTitle><Pagination><StartPage>156688</StartPage><MedlinePgn>156688</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cyto.2024.156688</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1043-4666(24)00191-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This longitudinal prospective study aims to investigate the potential of circulating calprotectin (cCLP) as a biomarker in persistent olfactory dysfunctions following COVID-19 infection.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirty-six patients with persistent hyposmia or anosmia post COVID-19 were enrolled (HT0) and re-evaluated after three months of olfactory training (HT1). Two control groups included 18 subjects without olfactory defects post COVID-19 (CG1) and 18 healthy individuals (CG2). Nasal brushing of the olfactory cleft and blood collection were performed to assess circulating calprotectin levels.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Higher calprotectin levels were observed in serum and nasal supernatant of hyposmic patients (HT0) compared to control groups (CG1 and CG2). Post-olfactory training (HT1), olfactory function improved significantly, paralleled by decreased calprotectin levels in serum and nasal samples. Circulating calprotectin holds potential as a biomarker in persistent olfactory dysfunctions after COVID-19. The decrease in calprotectin levels post-olfactory training implies a role in monitoring and evaluating treatment responses.</AbstractText><AbstractText Label="DISCUSSION AND CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings contribute to the growing literature on potential biomarkers in post-COVID-19 olfactory dysfunctions and underscore the importance of investigating novel biomarkers for personalized patient management. Nevertheless, further studies are needed to validate the application of calprotectin assay in nasal diseases and its correlation with nasal cytology.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Francavilla</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, University of Rome "Tor Vergata", Rome 00133 Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velletrani</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, University of Rome "Tor Vergata", Rome 00133 Italy. Electronic address: gianluca.velletrani@ptvonline.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiorelli</LastName><ForeName>Denise</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of "Tor Vergata", Rome 00133 Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maurantonio</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, University of Rome "Tor Vergata", Rome 00133 Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passali</LastName><ForeName>Francesco Maria</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, University of Rome "Tor Vergata", Rome 00133 Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schirinzi</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Rome "Tor Vergata", Rome 00133 Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernardini</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of "Tor Vergata", Rome 00133 Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Girolamo</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, University of Rome "Tor Vergata", Rome 00133 Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuccetelli</LastName><ForeName>Marzia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of "Tor Vergata", Rome 00133 Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cytokine</MedlineTA><NlmUniqueID>9005353</NlmUniqueID><ISSNLinking>1043-4666</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039841">Leukocyte L1 Antigen Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086582" MajorTopicYN="Y">Anosmia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039841" MajorTopicYN="Y">Leukocyte L1 Antigen Complex</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000857" MajorTopicYN="N">Olfaction Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Calprotectin</Keyword><Keyword MajorTopicYN="N">Hyposmia</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Nasal brush</Keyword><Keyword MajorTopicYN="N">Olfaction</Keyword><Keyword MajorTopicYN="N">Olfactory training</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>26</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>4</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>4</Day><Hour>18</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38963942</ArticleId><ArticleId IdType="doi">10.1016/j.cyto.2024.156688</ArticleId><ArticleId IdType="pii">S1043-4666(24)00191-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>